CoChat

The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme

Favier, Romain, Crépin, Sabrina · 2018 · Clinical Trials

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Background/aims: Accurate information on harms arising from medical interventions is essential for assessing benefit–risk ratios. Since 2004, there has been an extension of the Consolidated Standards of Reporting Trials statement for reporting harms data in publications on randomized clinical trials. The objective of our study was to assess the quality of this reporting from academic randomized clinical trials on drugs. Methods: We searched for articles on randomized clinical trials funded between 2004 and 2008 by the “Programme Hospitalier de Recherche Clinique.” We included all published randomized clinical trials that assessed drugs. Harm-related data were extracted and compared with the Consolidated Standards of Reporting Trials Harms extension, and the space in the articles devoted to harms data was measured. Results: In total, 37 randomized clinical trials met the inclusion criteria. The median harm score was 9/18. In 73.0% of the randomized clinical trials, the reporting of adverse events was selective. Less than 50% of articles provided information on reasons for drug discontinuation that were related to adverse events. The score and the space allocated to harms were higher in antineoplastic and immunomodulating drugs randomized clinical trials, while the median proportion of the space in the results section allocated to harms was 16.8%. In 67.6% of the articles, the space allocated to the authors’ list and affiliations was greater than the space in the results section allocated to descriptions of harms. No significant improvement in the score or the space allocation was observed during the study period. Conclusion: Reporting of harms in French academic drug randomized clinical trials is suboptimal; moreover, this shortcoming is a critical barrier to evaluating the benefit–risk ratio of drug randomized clinical trials. Thus, the authors should be encouraged to adhere to the Consolidated Standards of Reporting Trials Harms extension.

Overview

Integrity signals

Registry

Crossref · 10.1177/1740774518760565

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 66 references

Research works printed but not linked: 1

  1. Rozenberg P, 2012, Am J Obstet Gynecol, 206, 206

Cited by

See all 19

Metadata

Authors
Favier, R., & Crépin, S.
Affiliations
Centre Hospitalier Universitaire de Limoges (FR)
Corresponding author
Crépin, Sabrina
Venue
Clinical Trials
Published
2018-03-02
Volume
15
Issue
3
Pages
257-267
ISSN
  • 1740-7745 (ISSN-L)
  • 1740-7753
OpenAlex
W2790844534
Cited by
19
References
66
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3
FWCI
2.10
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Clinical Trials (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
harms reporting, adverse events, risk-benefit assessment, clinical drug trials, reporting quality, anticancer agents, immunomodulators
MeSH terms
Data Accuracy, Adult, Child, Preschool, France, Humans, Periodicals as Topic, Publishing, Research Design, Randomized Controlled Trials as Topic, Adverse Drug Reaction Reporting Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme. https://app.cochat.ai/papers/10.1177/1740774518760565
The paper
Favier, R., & Crépin, S. (2018). The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme. Clinical Trials. https://doi.org/10.1177/1740774518760565

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.